Hospira (NYSE:HSP) hit a new 52-week high Friday as it is currently trading at $37.97, above its previous 52-week high of $37.78 with 363,823 shares traded as of 9:45 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Hospira (NYSE: HSP) hit a new 52-week high Friday as it is currently trading at $37.97, above its previous 52-week high of $37.78 with 363,823 shares traded as of 9:45 a.m. ET. Average volume has been 1.2 million shares over the past 30 days. Hospira has a market cap of $5.84 billion and is part of the health care sector and drugs industry. Shares are up 15.7% year to date as of the close of trading on Thursday. Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow. You can view the full Hospira Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..